Evidence map›Paper›PMID 41594634›Full record

ReviewBiomolecules2026

From Phytochemistry to Oncology: The Role of Bakuchiol in the Treatment of Breast Cancer.

Magdalena Czarnecka-Czapczyńska, David Aebisher, Alina Pietryszyn-Bilińska, Magdalena Moś, Sara Czech, Jakub Szpara, Dorota Bartusik-Aebisher, Aleksandra Kawczyk-Krupka

Abstract readReview
In one paragraph

Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Magdalena Czarnecka-CzapczyńskaDepartment of Internal Diseases, Angiology and Physical Medicine, Center for Laser Diagnostics and Therapy, Medical University of Silesia, Batorego 15, 41-902 Bytom, Poland.ORCID 0000-0003-3951-6402
David AebisherDepartement of Photomedicine and Physical Chemistry, Collegium Medicum, Faculty of Medicine, Rzeszów University, 35-310 Rzeszów, Poland.ORCID 0000-0002-2661-6570
Alina Pietryszyn-BilińskaDepartment of Internal Diseases, Angiology and Physical Medicine, Center for Laser Diagnostics and Therapy, Medical University of Silesia, Batorego 15, 41-902 Bytom, Poland.ORCID 0000-0001-9783-6258
Magdalena MośSpecialist Hospital No. 2, Department of Internal Diseases, Angiology and Physical Medicine, Center for Laser Diagnosis and Therapy, Batorego Street 15, 41-902 Bytom, Poland.
Sara CzechEnglish Division Science Club, Collegium Medicum, Faculty of Medicine, 35-310 Rzeszów, Poland.
Jakub SzparaEnglish Division Science Club, Collegium Medicum, Faculty of Medicine, 35-310 Rzeszów, Poland.
Dorota Bartusik-AebisherDepartment of Biochemistry and General Chemistry, Collegium Medicum, Faculty of Medicine, Rzeszów University, 35-310 Rzeszów, Poland.ORCID 0000-0002-5557-5464
Aleksandra Kawczyk-KrupkaDepartment of Internal Diseases, Angiology and Physical Medicine, Center for Laser Diagnostics and Therapy, Medical University of Silesia, Batorego 15, 41-902 Bytom, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bakuchiol (BAK), a natural meroterpenoid with antioxidant, anti-inflammatory and anticancer properties, has recently gained attention as a potential adjunct in breast cancer therapy. This review contextualizes breast cancer as a major global health challenge and highlights BAK as a bioactive compound capable of modulating pathways relevant to tumor development and progression. A structured literature search identified studies examining its molecular activity, pharmacological profile, and effects on breast cancer cells and stem cells. Results show that BAK influences oxidative stress regulation, mitochondrial function, apoptosis and estrogen receptor signaling while also affecting PI3K/AKT, MAPK, NF-κB, and EMT-related pathways. In breast cancer models, BAK acts as a selective phytoestrogen, induces S-phase arrest, activates the ATM/ATR-Chk1/Chk2 axis, and triggers mitochondrial apoptosis, particularly in ERα-positive cells. It also suppresses breast cancer stem-cell renewal, promotes BNIP3- and DAPK2-mediated apoptosis, reduces metabolic and transcriptional drivers of metastasis, and shows enhanced anticancer activity in derivative forms. These findings suggest that BAK may provide therapeutic benefit across several mechanisms central to breast cancer biology. In this review, the inclusion criteria encompassed publications describing the action of bakuchiol, its chemical and pharmacological properties, as well as its role in the treatment of various conditions, including cancers. Exclusion criteria included works not related to BAK or its therapeutic use in breast cancer, as well as publications that did not meet basic scientific standards, such as lacking methodological rigor or presenting a low level of scientific evidence. However, current evidence is predominantly in vitro, and limitations such as poor bioavailability and lack of clinical validation underscore the need for further in vivo and translational studies before therapeutic application can be established.

Indexed as

Antineoplastic Agents, PhytogenicBreast NeoplasmsPhenolsAnimalsApoptosisFemaleHumansSignal TransductionAntineoplastic Agents, PhytogenicbakuchiolPhenolsbakuchiolbakuchiol extractionbakuchiol in treatmentbreast cancermolecular mechanismmolecular pathways

Identifiers

PMID41594634
PMCPMC12838981

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.